Customize your JAMA Network experience by selecting one or more topics from the list below.
Chua K, Conti RM. Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014. JAMA Intern Med. 2017;177(5):736–739. doi:https://doi.org/10.1001/jamainternmed.2017.0252
In 2007, Mylan obtained the right to EpiPen, the most widely used epinephrine auto-injector for serious allergic reactions.1,2 Since then, Mylan has increased the list price for EpiPen from $94 to $609.2 In part due to patient outcry over rising out-of-pocket spending, Mylan released a $300 generic EpiPen in December 2016.3
Whether generic EpiPen decreases out-of-pocket spending depends largely on insurers’ benefit design. To date, the generosity of EpiPen coverage has not been well characterized. We assessed EpiPen out-of-pocket spending between January 2007 and December 2014 among the commercially insured, a population that accounts for 70% of annual EpiPen prescriptions.1
Create a personal account or sign in to: